418,419,420 This activation holds the ability to modulate food consumption by reducing food intake and conveying signals of satiety to the brain
FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes , (2016)
Retatrutide is a synthetic triple receptor agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR)
GLP-1 agonists are potent medications that require a prescription and medical supervision
Week 1-4: Start with the lowest dose, usually around 1 mg once weekly
Researchers should consult primary sources and regulatory guidance for protocol-specific decisions